ESPE Yearbook of Paediatric Endocrinology

J Clin Endocrinol Metab. 2022 Jun 6:dgac349. PMID: 35666195, doi: 10.1210/clinem/dgac349. Brief Summary: This paper reports the adult height of 161 transgender girls (registered male at birth) from the Amsterdam Cohort of Gender Dysphoria. It finds no difference in adult height between use of standard and high estrogen doses. There is currently very little information on...

Eur J Endocrinol. 2018 Oct 12;179(5):R219–R237.doi: 10.1530/EJE-18-0227. PubMed ID: 30049812The rapidly increasing number of adolescents with gender dysphoria represents a challenge for psychiatric assessments and the endocrine management of those who are considered to warrant gender change. The diagnostics are more than complicated and the clinical management from ...

To read the full abstract: J Clin Endocrinol Metab. 2017 Jul ;102 (7):2356-2363[Comments on 6.6, 6.7 and 6.8] These 3 papers deal with endocine pharmacological treatment of patients with GD.The first article by Chew et al. (6.6), from Australia, systematically reviews different pharmacolo...

Brief summary: This paper investigated the effect of pubertal suppression with GnRHa and gender affirming treatment with testosterone on the growth and final height of transgender boys. They found no negative effects, and even possibly a slight boost to adult height in comparison with target and predicted heights for birth-registered sex.One of the concerning features of transgender males is being able to identify with their cisgender peers in stature. I...

Brief summary: Concerns exist that transgender adolescents opting for gender affirming treatments may subsequently regret their decision. This large study from Amsterdam provides information that in early adulthood, 98% of their cohort continued to access these treatments.The Amsterdam Cohort of Gender Dysphoria is one of the largest ongoing studies on the long-term outcomes of gender affirming hormone treatments (GAH). The authors presented outcomes at ...

Brief Summary: This prospective follow-up cohort study investigated bone mineral density in transgender individuals who had initiated GnRH analogue treatment before age 18 followed by sex hormone treatment for at least 9 years. At a median age 28.2 years, after using testosterone for a median 11.9 years (IQR 10.2-13.8), transmasculine individuals had mean z-scores close to 0 at the lumbar spine, total hip and femoral neck, similar to z-scores at the start of GnRH analogue trea...

To read the full abstract: J Clin Endocrinol Metab 2017 Nov 1;102(11):3869-3903This Endocrine Society endorsed paper is an update of the 2009 version, also published in JCEM, with clinical guidelines for endocrine management of patients with GD. The major focus is on adult patients but a large part is also focusing on children and adolescents with GD, contributed by co-authors with pediatric endo...

Clin Endocrinol (Oxf). 2022 Feb;96(2):165-174. PMID: 34668586, doi: 10.1111/cen.14614.Brief Summary: This retrospective case-control study used data from the international DSD registry to investigate the long-term outcomes of males born small for gestational age (SGA) with hypospadias/DSD. A large cohort of 179 boys (115 males born SGA; 64 appropriate for gestational age) was investigated for growt...

To read the full abstract: J Clin Endocrinol Metab. 2020, Mar 1; 105. doi: https://academic.oup.com/jcem/article-abstract/105/3/e222/5609091?redirectedFrom=fulltextThis cross-sectional study collected measures of genital development from 181 premature neonates, 378 term neonates, 308 babies up to 24 months, and in 111 babies with atypical geni...

To read the full abstract: J Clin Endocrinol Metab. 2019, Oct 1; 104: 4366–81. doi: https://www.ncbi.nlm.nih.gov/pubmed/31127831This retrospective observational study compared long-term health outcomes between 46,X/46,XY individuals diagnosed early in life due to genital anomalies (n =35) and those diagnosed later due other reasons (n =28). Data came from 16 clinic...